Clinical Trials Sponsored by Institute of Hematology & Blood Diseases Hospital, China

Total 249 results

Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

Transplant-Related Disorder

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML

Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Connective Tissue Diseases | Immune Thrombocytopenia | Autoantibodies | Evan Syndrome

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

Allergic Transfusion Reaction

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

AML | Refractory | Relapsed

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Platelet Transfusion Refractoriness | Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

Hemophilia A

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

C-KIT Mutation
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Treatment

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Anti-CD38 Antibody Treating Evans Syndrome (2023-D-ES)

Treatment | Evan Syndrome

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Refractory/Relapsed Autoimmune Hemolytic Anemia

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Acute Lymphoid Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

B Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Treatment

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

Thrombotic Microangiopathies | Hematopoietic Stem Cell Transplantation

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Refractory/Relapsed Autoimmune Hemolytic Anemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Essential Thrombocytopenia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Essential Thrombocytopenia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

AML

China
Institute of Hematology & Blood Diseases Hospital...

Terminated

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment (BID-PERAL)

Acquired Pure Red Cell Aplasia

China
Institute of Hematology & Blood Diseases Hospital...
YL-Pharma

Recruiting

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Relapsed/Refractory Large Granular T Lymphocytic Leukemia

China
wang, jianxiang

Recruiting

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | CEBPA Double Mutation

China
Zhu Xiaofan

Recruiting

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

B Lymphoblastic Lymphoma | B Lymphocytic Leukemia

China
Institute of Hematology & Blood Diseases Hospital...
YL-Pharma

Completed

Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Relapsed/Refractory Large Granular T Lymphocytic Leukemia

China
Institute of Hematology & Blood Diseases Hospital...
YL-Pharma

Terminated

PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Autoimmune Hemolytic Anemia | Failure of Two Rounds of Treatment

China
Qiu Lugui

Recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Diffuse Large B-cell Lymphoma | Peripheral T Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...
Kanglin Biotech

Recruiting

Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

Transfusion-dependent Beta-Thalassemia

China
Institute of Hematology & Blood Diseases Hospital...
Sinocelltech Ltd.

Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

Gene Therapy | Transfusion-dependent Beta-Thalassemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Cyclophosphamide Added to Standard Immunosuppressive Therapy With Eltrombopag as Front-line Therapy in Patients With Severe Aplastic Anemia

Severe Aplastic Anemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
Institute of Hematology & Blood Diseases Hospital

Recruiting

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

Polycythemia Vera

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (AHA2023)

Acquired Hemophilia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation | Hematological Disease

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Avatrombopag Combined With IST as First-line Treatment for SAA

Severe Aplastic Anemia

China

Clinical Trials Sponsored by Institute of Hematology & Blood Diseases Hospital, China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations